Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer

Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer

Introduction Adaptive ChemoTherapy for Ovarian cancer (ACTOv) is a phase II, multicentre, randomised controlled trial, evaluating an adaptive therapy (AT) regimen with carboplatin in women with relapsed, platinum-sensitive high-grade serous or high-grade endometrioid cancer of the ovary, fallopian t...

Full description

Saved in:
Bibliographic Details
Main Authors: Michelle Lockley, Kathy Robinson, Rowan Miller, Charlie Gourley, Nicholas Counsell, Iain Mcneish, Trevor Graham, Uma Anne Mukherjee, Helen Hockings, Apini Patel, Priya Narayanan, Katie Wilkinson, Harjot Dhanda, Alexander R A Anderson
Format: Article
Language:English
Published: BMJ Publishing Group 2024-12-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/12/e091262.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/14/12/e091262.full

Similar Items